TCIM
SLS icon

TIAA CREF Investment Management’s SELLAS Life Sciences SLS Stock Holding History

TIAA CREF Investment Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-21
Closed -$19K – 3170
2017
Q1 		$19K Hold
21
– – ﹤0.01% 3072
2016
Q4 		$62K Buy
+21
New +$122K ﹤0.01% 3099

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TIAA CREF Investment Management's SLS Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of SELLAS Life Sciences (SLS) in Q2 2017, closing a stake of 21 shares — an estimated $19K sold.

TIAA CREF Investment Management first reported a position in SLS in Q4 2016 and held it in 2 quarters. The position peaked at $62K in Q4 2016. 34 funds tracked by Wall St. Rank hold SLS as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining SELLAS Life Sciences position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 21 SELLAS Life Sciences shares in Q2 2017, an estimated $19K.
  • TIAA CREF Investment Management first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 2 quarters.
  • TIAA CREF Investment Management's SELLAS Life Sciences position peaked at $62K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.